STOCK TITAN

Vor Biopharma (VOR) director awarded 57,162 stock options at $14.09

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vor Biopharma director Wouter Joustra received a stock option grant covering 57,162 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 10, 2036. One thirty-sixth of the award vests monthly starting July 11, 2026, contingent on continued service. Following this compensation-related grant, Joustra holds 57,162 options directly and there were no open-market buys or sales reported.

Positive

  • None.

Negative

  • None.
Insider Joustra Wouter
Role null
Type Security Shares Price Value
Grant/Award Stock option (right to buy) 57,162 $0.00 --
Holdings After Transaction: Stock option (right to buy) — 57,162 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 57,162 options Stock option (right to buy) granted to director
Exercise price $14.09 per share Strike price for common stock under the option
Underlying shares 57,162 shares Common stock underlying the option grant
Post-grant derivative holdings 57,162 options Total options held following the transaction
Vesting commencement July 11, 2026 One thirty-sixth vests monthly from this date
Expiration date June 10, 2036 Final expiration of the stock option grant
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
vesting financial
"shares subject to the option shall vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price: 14.0900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-10T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common stock financial
"underlying_security_title: Common stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
grant/award acquisition financial
"transaction_action: grant/award acquisition"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Joustra Wouter

(Last)(First)(Middle)
500 BOYLSTON STREET, SUITE 1350

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)$14.0906/11/2026A57,162 (1)06/10/2036Common stock57,162$057,162D
Explanation of Responses:
1. One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
/s/ Adi Osovsky, Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Vor Biopharma (VOR) director Wouter Joustra report on this Form 4?

Wouter Joustra reported receiving a stock option grant for 57,162 shares of Vor Biopharma common stock. The options were awarded as compensation, not through open-market buying, and are held directly following the transaction.

What is the exercise price of Wouter Joustra’s Vor Biopharma stock options?

The granted stock options have an exercise price of $14.09 per share. This is the price at which Joustra can buy Vor Biopharma common stock if and when the options vest and he chooses to exercise them.

How many Vor Biopharma shares are covered by Wouter Joustra’s new option grant?

The option grant covers 57,162 shares of Vor Biopharma common stock. All 57,162 options are reported as directly owned following the grant, with no other derivative positions shown in this filing.

When do Wouter Joustra’s Vor Biopharma options start vesting and over what schedule?

One thirty-sixth of the option grant vests on July 11, 2026, then monthly thereafter. Vesting continues each month, subject to Joustra’s continued service through each vesting date, gradually making more options exercisable over time.

When do Wouter Joustra’s Vor Biopharma stock options expire?

The stock options expire on June 10, 2036. After this expiration date, any unexercised options become worthless, so they must vest and be exercised before that time to convert into common shares.

Did Wouter Joustra buy or sell Vor Biopharma shares on the market in this Form 4?

No open-market buys or sales were reported. The Form 4 shows an acquisition coded as a grant or award of stock options, which is a compensation event rather than a market trade in Vor Biopharma shares.